PegBio Co ROIC

Mitä PegBio Co tekee? PegBio Co Ltd is a biotechnology company based in Hangzhou, China, operating within the healthcare sector. The company focuses on the research, development, and production of innovative drugs targeting chronic disease treatment. PegBio is set to go public with an IPO scheduled for May 27, 2025, under the ticker 2565.HK. The company's website is https://www.pegbio.com/. PegBio's primary product, PB-119, is described as a self-developed, near-commercialized long-acting glucagon-like peptide 1 (GLP-1) receptor agonist. GLP-1 is a peptide hormone involved in blood sugar regulation. The company also lists several product candidates, including PB-718, PB-1902, PB-722, PB-2301, and PB-2309. These products are intended for the treatment of various chronic and metabolic conditions, such as type 2 diabetes mellitus (T2DM), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia. Congenital hyperinsulinemia is a rare endocrine disorder characterized by persistent low blood sugar levels. PegBio's focus areas include metabolic diseases and chronic conditions requiring ongoing therapeutic management. The company's operational headquarters is located in Hangzhou, Zhejiang Province, China. As a biotechnology firm, PegBio operates within the broader healthcare industry, emphasizing drug development for unmet medical needs in chronic disease management. PegBio Co on yksi Eurpooliin suosituimmista yhtiöistä.